[Phase 2 study with cis-dichlorodiaminoplatinum (II) in advanced solid tumors]

Area of Science:

• Oncology
• Pharmacology
• Cancer Research

Context:

• Investigating novel platinum-based chemotherapy agents for advanced solid malignancies.
• Evaluating treatment efficacy in heavily pretreated patient populations with progressive disease.
• Assessing the safety profile of cis-Dichlorodiammineplatinum(II) in a clinical setting.

Purpose:

• To determine the efficacy and toxicity of cis-Dichlorodiammineplatinum(II) in patients with advanced solid tumors.
• To evaluate objective tumor regression and disease stabilization rates.
• To assess the safety and tolerability of the cis-Dichlorodiammineplatinum(II) regimen.

Summary:

• cis-Dichlorodiammineplatinum(II) was administered to 23 patients with advanced solid malignancies at a dose of 50 mg/m2 every 3 weeks.
• Objective tumor regression was observed in 4 patients (duration 1-4 months), and disease progression was halted for at least 1 month in 7 patients.
• No severe toxicities were encountered due to adequate fluid administration, electrolyte substitution, furosemide, and mannitol.

Impact:

• Highlights the potential of cis-Dichlorodiammineplatinum(II) as a treatment option for advanced solid tumors, particularly in heavily pretreated patients.
• Demonstrates that effective management of hydration and electrolytes can mitigate severe toxicity associated with platinum-based chemotherapy.
• Provides data supporting further investigation into platinum-based therapies for refractory cancers.